NasdaqCM:TROV

Stock Analysis Report

Executive Summary

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors.

Rewards

Revenue is forecast to grow 52.41% per year

Earnings have grown 3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of -21.7% per year for the next 3 years

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($230K)

+ 3 more risks


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has TrovaGene's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TROV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.7%

TROV

-0.6%

US Biotechs

-0.3%

US Market


1 Year Return

-68.3%

TROV

14.9%

US Biotechs

18.6%

US Market

Return vs Industry: TROV underperformed the US Biotechs industry which returned 14.9% over the past year.

Return vs Market: TROV underperformed the US Market which returned 18.6% over the past year.


Shareholder returns

TROVIndustryMarket
7 Day-5.7%-0.6%-0.3%
30 Day-20.8%9.4%2.2%
90 Day-29.3%14.9%5.6%
1 Year-68.3%-68.3%15.9%14.9%21.1%18.6%
3 Year-99.3%-99.3%28.1%24.1%45.6%36.2%
5 Year-99.6%-99.6%6.8%1.9%71.1%52.2%

Price Volatility Vs. Market

How volatile is TrovaGene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TrovaGene undervalued compared to its fair value and its price relative to the market?

1.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TROV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TROV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TROV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TROV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TROV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TROV is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3.1x).


Next Steps

Future Growth

How is TrovaGene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-21.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TROV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TROV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TROV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TROV's revenue (52.4% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: TROV's revenue (52.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TROV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TrovaGene performed over the past 5 years?

3.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TROV is currently unprofitable.

Growing Profit Margin: TROV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TROV is unprofitable, but has reduced losses over the past 5 years at a rate of 3% per year.

Accelerating Growth: Unable to compare TROV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TROV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: TROV has a negative Return on Equity (-245.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is TrovaGene's financial position?


Financial Position Analysis

Short Term Liabilities: TROV's short term assets ($10.0M) exceed its short term liabilities ($4.2M).

Long Term Liabilities: TROV's short term assets ($10.0M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: TROV is debt free.

Reducing Debt: TROV has no debt compared to 5 years ago when its debt to equity ratio was 119.7%.


Balance Sheet

Inventory Level: TROV has a low level of unsold assets or inventory.

Debt Coverage by Assets: TROV's debt is not covered by short term assets (assets are -4.4931440704756E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TROV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TROV has less than a year of cash runway if free cash flow continues to grow at historical rates of 36.8% each year.


Next Steps

Dividend

What is TrovaGene's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TROV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TROV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TROV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TROV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TROV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of TrovaGene's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Tom Adams (76yo)

3.8yrs

Tenure

US$377,192

Compensation

Dr. Thomas H. Adams, also known as Tom, Ph.D., has been Chief Executive Officer of TrovaGene, Inc., since June 2018 and its Executive Chairman of the Board since November 2018. He served as an Interim Chie ...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD377.19K) is about average for companies of similar size in the US market ($USD508.62K).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.1yrs

Average Tenure

Experienced Management: TROV's management team is considered experienced (4.1 years average tenure).


Board Age and Tenure

9.7yrs

Average Tenure

69yo

Average Age

Experienced Board: TROV's board of directors are considered experienced (9.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 215.3%.


Management Team

  • Tom Adams (76yo)

    Executive Chairman of the Board & CEO

    • Tenure: 3.8yrs
    • Compensation: US$377.19k
  • Mark Erlander (59yo)

    Chief Scientific Officer

    • Tenure: 6.8yrs
    • Compensation: US$908.52k
  • Beth Anderson

    VP of Finance & Administration

    • Tenure: 4.4yrs
  • Vicki Kelemen

    Vice President of Investor Relations & Clinical Development.

    • Tenure: 1.9yrs
  • George Samuel

    VP & General Counsel

    • Tenure: 0yrs
  • Brigitte Lindsay

    Vice President of Finance

    • Tenure: 0yrs

Board Members

  • Charles Cantor (76yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Tom Adams (76yo)

    Executive Chairman of the Board & CEO

    • Tenure: 3.8yrs
    • Compensation: US$377.19k
  • K. Hirth (67yo)

    Member of Scientific Advisory Board

    • Tenure: 5.3yrs
  • Paul Billings (67yo)

    Member of Scientific Advisory Board

    • Tenure: 7.1yrs
    • Compensation: US$35.85k
  • Rod Markin (62yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$87.01k
  • John Brancaccio (71yo)

    Independent Director

    • Tenure: 14yrs
    • Compensation: US$81.68k
  • Gary Jacob (72yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$65.68k
  • Carlo Croce

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Riccardo Dalla-Favera (67yo)

    Member of Scientific Advisory Board

    • Tenure: 9.7yrs
  • Brunangelo Falini

    Member of Scientific Advisory Board

    • Tenure: 9.7yrs

Company Information

TrovaGene, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TrovaGene, Inc.
  • Ticker: TROV
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.762m
  • Shares outstanding: 7.74m
  • Website: https://trovageneoncology.com

Number of Employees


Location

  • TrovaGene, Inc.
  • 11055 Flintkote Avenue
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TROVNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 2003
XE7CDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2003

Biography

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/06 23:58
End of Day Share Price2019/12/06 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.